Cannovum Cannabis AG Logo

Cannovum Cannabis AG

Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.

27N0 | DU

Overview

Corporate Details

ISIN(s):
DE000A30VHF2 (+2 more)
LEI:
894500IT61F9P85YMM31
Country:
Germany
Address:
Stresemannstraße 23, 10963 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cannovum Cannabis AG is a pharmaceutical company that operates as an importer, wholesaler, and manufacturer of medical cannabis products. The company focuses on providing patients with cannabis-based therapies, supported by medical-scientific education and distribution services. As one of the first fully licensed cannabis companies to be publicly listed in Germany, Cannovum is leveraging its market position to expand into the emerging recreational cannabis sector. This strategic expansion includes providing cultivation areas and infrastructure for cannabis social clubs to address the adult-use consumer market following recent legalization.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-27 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2025-02-26 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2024-08-01 07:36
Regulatory News Service
Cannovum Cannabis AG: Far-reaching partnership with H.i. Greeny+ GmbH and H.i C…
English 9.4 KB
2024-06-26 09:34
Regulatory News Service
Cannovum Cannabis AG: 'Cannabis for Germany', sale of fake hemp in 1,000 Aldi S…
English 9.0 KB
2024-06-07 07:00
Legal Proceedings Report
Cannovum Cannabis AG: Bundestag confirms Cannovum Cannabis AG's business model …
English 7.6 KB
2024-06-04 10:20
Share Issue/Capital Change
Cannovum Cannabis AG: Cash capital increase from authorized capital with subscr…
English 5.9 KB
2024-03-22 11:45
Regulatory News Service
Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of Apri…
English 9.5 KB
2024-03-05 09:30
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.0 KB
2024-03-05 06:59
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.1 KB
2024-02-23 15:51
Regulatory News Service
Cannovum Cannabis AG: Bundestag approves legalization of cannabis in Germany, h…
English 8.1 KB
2024-02-02 09:37
Earnings Release
Cannovum Cannabis AG: April 2024 starts the legalization of cannabis in Germany…
English 7.8 KB
2023-11-14 15:55
Board/Management Information
Cannovum Cannabis AG: High-profile business leaders from advertising and retail…
English 7.3 KB
2023-11-06 13:39
Regulatory News Service
Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partner…
English 10.6 KB
2023-08-07 07:30
Regulatory News Service
Cannovum Cannabis AG: Exclusive partnership and million-dollar sales potential …
English 9.2 KB
2023-07-17 10:47
Regulatory News Service
Cannovum Cannabis AG: New partner strengthens offer for private cultivation of …
English 10.4 KB

Automate Your Workflow. Get a real-time feed of all Cannovum Cannabis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cannovum Cannabis AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cannovum Cannabis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.